DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

Regeneron Pharmaceuticals (NASDAQ: REGN)

396.61 -15.98 (-3.87%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

REGN $396.61 -3.87%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $416.10
Previous Close $412.59
Daily Range $393.07 - $420.53
52-Week Range $392.35 - $605.93
Market Cap $41.3B
P/E Ratio 81.54
Dividend (Yield) $0.00 (0.0%)
Volume 1,432,629
Average Daily Volume 950,555
Current FY EPS $9.78




Drug Makers

Regeneron Pharmaceuticals (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website:

News & Commentary Rss Feed

Why Ophthotech Corporation Shares Tumbled 31% in January

The launch of trials in dry age-related macular degeneration failed to spark shares last month.

All Biotech Is Going Lower - Cramer's Lightning Round (2/5/16)

'Mad Money' Lightning Round: Expect More Pain From Regeneron Pharmaceuticals

Regeneron (REGN) to Report Q4 Earnings: What's in Store?

3 Things to Look for in Regeneron Pharmaceuticals Inc.'s Earnings

From Eylea sales to the late-stage pipeline, here are the three areas this Fool will be watching in Regeneron's fourth-quarter report.

EWT, PTH: Big ETF Outflows

Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention

Avalanche (AAVL) Set to Acquire Annapurna Therapeutics

Why Regeneron Pharmaceuticals Shares Fell 23% in January

The broad market sell-off hit biotech stocks hard last month.

Ignore Regeneron Pharmaceuticals, Inc: Here Are 3 Better Buys Right Now

Thinking about investing in Regeneron? Here are three names you might want to consider instead.

See More REGN News...

REGN's Top Competitors

REGN $396.61 (-3.87%)
Current stock: REGN
AMGN $145.04 (-3.25%)
Current stock: AMGN
GILD $85.14 (-1.78%)
Current stock: GILD
BIIB $263.86 (-3.44%)
Current stock: BIIB